EIDD-036

EIDD-036
臨床資料
其他名稱	EPRX-036; Progesterone 20-oxime; P4-20-O; Pregn-4-ene-3,20-dione 20-oxime; 20-(Hydroxyimino)pregn-4-en-3-one
藥物類別	神經甾體
識別資訊
	IUPAC命名法 (8S,9S,10R,13S,14S,17S)-17-[(Z)-N-hydroxy-C-methylcarbonimidoyl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; ;
CAS號	211302-60-2
PubChem CID	86692077;
化學資訊
化學式	C21H31NO2
摩爾質量	329.48 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C/C(=N/O)/[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C;
	InChI InChI=1S/C21H31NO2/c1-13(22-24)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19,24H,4-11H2,1-3H3/b22-13-/t16-,17+,18-,19-,20-,21+/m0/s1; Key:WGIMTKVWTJMLDA-ODGMAUQTSA-N;

EIDD-036（或稱為EPRX-036，孕酮-20-肟，英語：progesterone 20-oxime，縮寫P4-20-O，20-(羥肟基)孕甾-4-烯-3-酮，20-(hydroxyimino)pregn-4-en-3-one）是一種含氮有機化合物，化學式C
21H
31NO
2，屬於一種可溶性孕酮衍生物，也是EIDD-1723（英語：EIDD-1723）的主要活性代謝產物^[1]^[2]^[3]^[4]。

參考文獻

^ Wali B, Sayeed I, Guthrie DB, Natchus MG, Turan N, Liotta DC, Stein DG. Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats. Neuropharmacology. October 2016, 109: 148–158. PMID 27267687. S2CID 19906601. doi:10.1016/j.neuropharm.2016.05.017.
^ Guthrie, D. B., Lockwood, M. A., Natchus, M. G., Liotta, D. C., Stein, D. G., & Sayeed, I. (2017). U.S. Patent No. 9,802,978. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US9802978B2/en
^ MacNevin CJ, Atif F, Sayeed I, Stein DG, Liotta DC. Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury. J. Med. Chem. October 2009, 52 (19): 6012–23. PMID 19791804. doi:10.1021/jm900712n.
^ Guthrie DB, Stein DG, Liotta DC, Lockwood MA, Sayeed I, Atif F, Arrendale RF, Reddy GP, Evers TJ, Marengo JR, Howard RB, Culver DG, Natchus MG. Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury. ACS Med Chem Lett. May 2012, 3 (5): 362–6. PMC 4025794 . PMID 24900479. doi:10.1021/ml200303r.